Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

• the present invention relates to pharmaceutical compositions of Edoxaban, processes for their preparation and their medical use.
• Edoxaban is a basic compound that exhibits favorable solubility in a strongly acidic aqueous solution, but reduced solubility in an aqueous solution having a pH in the neutral region (e.g., a neutral buffer). Therefore, a solid formulation containing Edoxaban or a pharmaceutically acceptable salt thereof as an active ingredient exhibits a poor dissolution property in an aqueous solution having a pH in the neutral region.
• WO 2010/147169 Al discloses reducing the proportion of Edoxaban in the pharmaceutical composition (0.5 -10%), which however results in big dosage forms that are difficult to swallow and negatively impact patient compliance to the therapy.
• WO 2011/115067 Al it is known from WO 2011/115067 Al that the dissolution property in the neutral region of a solid formulation containing Edoxaban is improved by keeping the maximum water content of granulated material containing Edoxaban during granulation at 10% or less.
• WO 2013/022059 Al discloses that the addition of an acid to formulations of Edoxaban seems to improve its dissolutions properties; however the examples relate to compositions containing very high amounts of acids, which thus reduce the drug load, as well as specific fillers, such as mannitol and pregelatinized starch.
• WO 2013/026533 Al discloses effervescent formulations of Edoxaban comprising a carbon dioxide forming agent, such as sodium bicarbonate, which need special precautions regarding manufacturing and packaging to prevent contact with moisture.
• the present disclosure provides a pharmaceutical composition
• a pharmaceutical composition comprising Edoxaban, or a pharmaceutically acceptable salt thereof, a water soluble vinylpyrrolidone polymer selected from the group consisting of povidone and copovidone, and a cellulose ether, and not comprising a sugar alcohol, a process for its preparation, a dosage form comprising such composition, and the use of said pharmaceutical composition and dosage form as a medicament.
• povidone refers to polyvinylpyrrolidone, a water-soluble polymer made from the monomer N-vinylpyrrolidone.
• copovidone refers to a water-soluble vinylpyrrolidone -vinyl acetate copolymer that contains the two components in a ratio of about 6:4.
• cellulose ether refers to derivatives of cellulose that are formed via partial of complete substitution of the hydrogen atoms of the hydroxyl groups of cellulose. Such reaction is known as etherification.
• granulating refers to the formation of relatively coarse or granular aggregate material as a powder by assembling and/or aggregating finer powder particles (agglomerate formation, or build-up granulation) and/or the formation of finer granules by breaking up coarser aggregates (disintegration, or break-down granulation). Granulation can
• Edoxaban free base or, preferably, a pharmaceutically acceptable salt thereof may be used. More preferably, the pharmaceutically acceptable salt of Edoxaban is Edoxaban tosylate. Particularly preferred is Edoxaban tosylate monohydrate.
• the pharmaceutical composition of the present invention comprises 5 to 80%, more preferably 8 to 50%, even more preferably 10 to 30% of Edoxaban, calculated as weight of the free base on the total weight of the composition.
• Povidone is preferably selected from the group consisting of povidone K12, K15, K17, K25, K30, K60, K90 and K120.
• Copovidone is preferably selected from the group consisting of Kollidon VA 64, Plasdone S-630 and Luvixol VA.
• the pharmaceutical composition of the present invention comprises 1 to 20%, more preferably 2 to 15%, even more preferably 3 to 10% of the water soluble vinylpyrrolidone polymer, calculated as weight of vinylpyrrolidone polymer on the total weight of the composition.
• the cellulose ether is preferably selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethylcellulose (EC), hydroxyethyl cellulose (HEC), carboxymethyl cellulose (CMC) and methylcellulose (MC), preferably hydroxypropyl methylcellulose, hydroxypropyl cellulose, ethyl cellulose or hydroxyethyl cellulose, most preferably hydroxypropyl methylcellulose.
• the pharmaceutical composition of the present invention comprises 1 to 20%, more preferably 2 to 15%, even more preferably 3 to 10% of the cellulose ether, calculated as weight of the cellulose ether on the total weight of the composition.
• the pharmaceutical composition of the invention can preferably contain further inactive ingredients, preferably selected from the group consisting of fillers, disintegrants and lubricants.
• fillers generally refers to substances which serve, for example, to form the body of the tablet in the case of tablets with small amounts of active agent. This means that fillers "dilute" the active agents in order to produce an adequate dosage form mixture.
• the normal purpose of fillers therefore, is to obtain a suitable dosage form size, preferably a suitable tablet size.
• suitable fillers are micro crystalline cellulose, dibasic calcium phosphate, lactose, talcum, calcium phosphate, magnesium carbonate, magnesium oxide, calcium sulphate, saccharose, monosaccharides, such as glucose, maltodextrin, dextrates, dextrin.
• Preferred fillers are micro crystalline cellulose, dibasic calcium phosphate and lactose monohydrate.
• Disintegrants expand and dissolve when wet causing the pharmaceutical composition to break apart in the digestive tract, releasing the active ingredients for absorption. They ensure that when the pharmaceutical composition is in contact with water, it rapidly breaks down into smaller fragments, facilitating dissolution.
• suitable disintegrants include crosslinked polymers, starches and modified starches.
• Preferred disintegrants are crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose
• Lubricants are generally used in order to reduce sliding friction. Suitable lubricants are, for example, sodium stearyl fumarate, magnesium stearate, glyceryl behenate, stearic acid and adipic acid. Preferred lubricants are sodium stearyl fumarate, magnesium stearate and glyceryl behenate. Formulation process
• compositions of the present invention are obtained by contacting Edoxaban, or a pharmaceutically acceptable salt thereof, with a water soluble
• vinylpyrrolidone polymer selected from the group consisting of povidone and copovidone, and a cellulose ether in a dry state or dispersed in the adequate amount of solvent) and, optionally, further inactive ingredients such as fillers and disintegrants with the proviso that sugar alcohols are excluded.
• wet granulation is used and water is used as preferred solvent.
• the wet granules are then dried.
• the dried granules are optionally sieved and blended with further ingredients, such as lubricants, and the final blend is compressed into tablets, or, alternatively, filled into capsules or sachets.
• dry granulation is used.
• the mixture is then blended and compacted using appropriate compacting machine.
• the compacted granules or slugs are then milled and passed through appropriate sieve, blended with further ingredients, such as lubricants, and the final blend is compressed into tablets, or, alternatively, filled into capsules or sachets.
• the composition of the present invention can be used as intermediate or as final dosage form.
• the composition of the present invention is used as intermediate, which is preferably further processed into a dosage form.
• the processing into a dosage form can be achieved by means of suitable methods, such as filling into sachets or capsules or by compressing into tablets. Therefore, the composition of the invention can be employed to prepare a dosage form, preferably an oral dosage form, more preferably a solid oral dosage form, in particular a capsule or a tablet.
• the dosage form can be a tablet, which can or cannot be film-coated. For this purpose, methods known in the art for film-coating a tablet may be employed.
• film-coatings can be prepared by using cellulose derivatives, poly(meth)acrylate, polyvinyl pyrrolidone, polyvinyl acetate phthalate, or natural rubbers such as carrageenan.
• Preferably the tablet is uncoated.
• the tablet of the invention can preferably have a hardness of not less than 30 N, more preferably not less than 50 N.
• the hardness is determined in accordance with Ph. Eur., 6.0, Chapter 2.9.8.
• the tablet of the invention can preferably have a friability of less than 3%, more preferably less than 2%, in particular 0.1 to 1.2%.
• the friability is determined in accordance with Ph. Eur., 6.0, Chapter 2.9.7.
• the tablet of the invention preferably can have a "content uniformity" of 93 to 107%, more preferably 95 to 105%, still more preferably 98 to 102%, particularly 99 to 101% of the average content.
• the "content uniformity" is determined in accordance with Ph. Eur., 6.0, Chapter 2.9.6.
• the above details regarding hardness, friability and content uniformity preferably relate to the non-film-coated tablet.
• the composition and/ or the dosage form according to the invention provides an immediate release of Edoxaban.
• the release profile of the dosage forms of the invention according to USP method (paddle, 900 ml, 0.1 n HC1 , 75 rpm, 37 'C) after 10 minutes usually indicates a content release of at least 75 %, preferably at least 85 %, especially at least 90 %.
• the release can be up to 95 %, preferably up to 100 %.
• the dosage form of the present invention can be administered independently from the meals of the patient, i.e. the dosage forms of the present invention are suitable to be administered before, during or after the meals.
• the dosage forms of the invention are administered once a day at a daily dose of 30 to 60 mg.
• the dosage form of the present invention preferably shows superior and pH independent dissolution and absorption characteristics upon administration, leading to high bioavailability and desirable plasma values, like desirable AUC (area under the curve from 0 to 48 hours after oral administration), C max and T max values.
• administration of the dosage form of the present invention results in a T max value of 0.5 to 3 hours, more preferably of 0.75 to 1.5 hours.
• administration of the dosage form of the present invention in a strength of 30 mg calculated for the free base of Edoxaban results in a C max value of 100 to 300 ng/ml, more preferably 150 to 250 ng/ml.
• administration of the dosage form of the present invention in a strength of 60 mg calculated for the free base of Edoxaban results in a C max value of 150 to 500 ng/ml, more preferably 200 to 350 ng/ml.
• administration of the dosage form of the present invention in a strength of 30 mg calculated for the free base of Edoxaban results in a AUC value of 500 to 3000 ng h/ml, more preferably 750 to 1500 ng h ml.
• the plasma values are an average of ten single measurement values, determined upon administration to 10 male humans having a body weight of about 75 kg.
• no specific fillers like sugar alcohols are needed and very good results can be obtained using common fillers like lactose, calcium phosphate and the like.
• high drug loads can be achieved, resulting in smaller dosage forms and improved patient compliance.
• Use of carbon dioxide forming agent is also avoided, which allows for cheap manufacturing and packaging. Also coating of the dosage forms can be avoided, leading to quicker and cheaper processing.
• Edoxaban tosylate monohydrate is blended with the two binders, half of the disintegrant and with the fillers in a high shear mixer. The mixture is then granulated with an adequate amount of water using a high shear granulation. The wet granules are then dried at 50°C. The dried granules are passed through a 0.8 mm screen and blended with the rest of the disintegrant and with the lubricant using an appropriate free fall blender. The final blend is compressed into tablets using a 9 mm round punch with a target weight of 200 mg.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=53177487

Family Applications (1)

Country Status (4)

Cited By (4)

Families Citing this family (3)

Citations (2)

Family Cites Families (3)

• 2015
  • 2015-05-13 WO PCT/EP2015/060656 patent/WO2016020080A1/en not_active Ceased
  • 2015-05-13 JP JP2016574064A patent/JP2017523149A/ja active Pending
  • 2015-05-13 EP EP15722530.1A patent/EP3177290B1/en not_active Not-in-force
  • 2015-05-13 US US15/501,518 patent/US20170231969A1/en not_active Abandoned

Patent Citations (2)

Also Published As

Similar Documents

Legal Events